DanielChoMD

Anatomic Pathology, Clinical Pathology

Assistant Professor, Medicine, New York Univ Sch of Med

Are you Dr. Cho?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 60 invites waiting!
Read the latest clinical news, personalized to your specialty.

Office
1101 Nott St
Ellis Hospital Laboratory, Dept Of Pathology
Schenectady, NY 12308
Phone+1 518-243-4050

Fax+1 518-262-5861

Dr. Daniel Cho, MD is a board certified pathologist in Schenectady, New York. He is currently licensed to practice medicine in New York and New Hampshire. He is affiliated with Ellis Medicine and is an Assistant Professor at New York Univ Sch of Med.

Albany Medical CenterResidency, Pathology-Anatomic and Clinical, 2007 - 2011
Albany Medical CenterResidency, Urology, 2003 - 2007
New York Presbyterian HospitalInternship, Transitional Year, 2001 - 2002
State University of New York Downstate Medical Center College of MedicineClass of 2001

PubMed

269 citations
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, Mayer Fishman, David F. McDermott
The Lancet. Oncology. 2018-03-01
148 citations
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M. Tannir, Salah Eddine Bentebibel, Patrick Hwu, Vassiliki A. Papadimitrakopoulou
Cancer Discovery. 2020-05-21
46 citations
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti
Journal of Clinical Oncology. 2021-07-13